Clinical Efficacy of Targeted Biologic Agents as Second-Line Therapy of Advanced Thyroid Cancer-Reference-Cited by-同舟云学术

Clinical Efficacy of Targeted Biologic Agents as Second-Line Therapy of Advanced Thyroid Cancer

Published:2013-10-23 Issue:12 Volume:18 Page:1262-1269
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Owonikoko Taofeek K.¹²,Chowdry Rajasree P.³,Chen Zhengjia²⁴,Kim Sungjin²,Saba Nabil F.¹²,Shin Dong M.¹²,Khuri Fadlo R.¹²

Affiliation:

1. Department of Hematology and Medical Oncology, School of Medicine, Atlanta, Georgia, USA

2. Winship Cancer Institute, Atlanta, Georgia, USA

3. Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA

4. Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA

Abstract

Learning Objectives List the therapeutic opportunities with tyrosine kinase inhibitors for advanced thyroid cancer, especially in the frontline setting. Describe and discuss the current knowledge and experience with salvage therapy with biologic agents for thyroid cancer.

Funder

Novartis Pharmaceuticals

NIH

Georgia Cancer Coalition Distinguished Cancer Scholar Award

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://pericles-gcp.literatumonline.com/doi/pdf/10.1634/theoncologist.2013-0250

Reference29 articles.

1. Increasing incidence of thyroid cancer in the United States, 1973–2002;Davies;JAMA,2006